Cue Biopharma, Inc. (CUE) News

Cue Biopharma, Inc. (CUE): $10.38

-0.25 (-2.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CUE News Items

CUE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CUE News Highlights

  • 500 - Internal server error
  • Over the past 21 days, the trend for CUE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • MA are the most mentioned tickers in articles about CUE.

Latest CUE News From Around the Web

Below are the latest news stories about Cue Biopharma Inc that investors may wish to consider to help them evaluate CUE as an investment opportunity.

Cue Biopharma Consensus Indicates Potential 164.6% Upside

Cue Biopharma with ticker code (CUE) now have 6 analysts in total covering the stock. The consensus rating is ''Strong_Buy''. The range between the high target price and low target price is between 33 and 27 and has a mean target at 30. Now with the previous closing price of 11.34 this indicates there is a potential upside of 164.6%. There is a 50 day moving average of 12.97 and the 200 moving average now moves to 13.21. The company has a market capitalisation of $356m. Visit the company website at: /> [stock_market_widget type="chart" symbol="CUE" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Cue Biopharma, a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chro...

DirectorsTalk | July 13, 2021

Cue Biopharma Consensus Indicates Potential 138.7% Upside

Cue Biopharma found using ticker (CUE) have now 6 analysts covering the stock. The analyst consensus points to a rating of ''Strong_Buy''. The target price ranges between 33 and 27 and has a mean target at 30. With the stocks previous close at 12.57 this would imply there is a potential upside of 138.7%. The day 50 moving average is 13.35 and the 200 day MA is 13.32. The company has a market cap of $390m. Visit the company website at: /> [stock_market_widget type="chart" symbol="CUE" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Cue Biopharma, a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug c...

DirectorsTalk | June 22, 2021

Cue Biopharma Consensus Indicates Potential 125.2% Upside

Cue Biopharma found using ticker (CUE) have now 6 analysts covering the stock. The analyst consensus points to a rating of ''Strong_Buy''. The range between the high target price and low target price is between 33 and 27 and has a mean target at 30. With the stocks previous close at 13.32 this now indicates there is a potential upside of 125.2%. There is a 50 day moving average of 13.21 and the 200 day MA is 13.35. The company has a market cap of $427m. Company Website: /> [stock_market_widget type="chart" symbol="CUE" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Cue Biopharma, a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and a...

DirectorsTalk | June 15, 2021

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021.

Intrado Digital Media | June 14, 2021

Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today that it has dosed the first patient in the Part B expansion phase of its Phase 1 monotherapy clinical trial of CUE-101 at the recommended Phase 2 dose of 4mg/kg.

Intrado Digital Media | June 10, 2021

Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting

CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, which is being held virtually from June 8-11, 2021. Anish Suri, president and chief scientific offi

Yahoo | June 3, 2021

Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patients body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting , which is being held virtually from June 8-11, 2021.

BioSpace | June 2, 2021

Cue Biopharma Consensus Indicates Potential 110.2% Upside

Cue Biopharma found using ticker (CUE) now have 6 analysts covering the stock with the consensus suggesting a rating of ''Strong_Buy''. The target price ranges between 33 and 27 and has a mean target at 30. Now with the previous closing price of 14.27 this indicates there is a potential upside of 110.2%. The 50 day moving average now sits at 12.89 and the 200 day MA is 13.26. The company has a market capitalisation of $450m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="CUE" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Cue Biopharma, a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, a...

DirectorsTalk | June 1, 2021

Cue Biopharma to Present a Corporate and Clinical Progress Update at the Upcoming Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE ), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient''s body, announced today that it will present at the Jefferies Virtual Healthcare Conference being held June 1-4, 2021. Cue Biopharma will provide a corporate update highlighting clinical progress with CUE-101, representative of the CUE-100 series and the Company''s lead Immuno-STAT (Selective Targeting and Alteration of T cells) platform-based therapeutic, in clinical trials for the treatment of patients with HPV+ recurrent/metastatic head and neck cancer. The presentation will also Full story available on Benzinga.com

Benzinga | May 26, 2021

Cue Biopharma Consensus Indicates Potential 114.3% Upside

Cue Biopharma found using ticker (CUE) have now 6 analysts covering the stock. The analyst consensus points to a rating of ''Strong_Buy''. The target price ranges between 33 and 27 and has a mean target at 30. Now with the previous closing price of 14 this indicates there is a potential upside of 114.3%. The 50 day MA is 12.65 and the 200 moving average now moves to 13.16. The market capitalisation for the company is $437m. Company Website: /> [stock_market_widget type="chart" symbol="CUE" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Cue Biopharma, a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead ...

DirectorsTalk | May 25, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.584 seconds.